Evidence brief for 15 May to 21 May 2021
For the period of 15 May to 21 May 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 15 May to 21 May 2021
Evidence brief for 08 May to 14 May 2021
For the period of 08 May to 14 May 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 08 May to 14 May 2021
Remdesivir, Tocilizumab, Baricitinib, and Favipiravir
Link to the HTAC Recommendation: HTAC Recommendations on COVID-19 Investigational Drugs Document Preview: